WANTAI BIOLOGICAL(SH:603392) Zheng Quan Zhi Xing·2025-08-13 12:19Core Viewpoint - The company, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., has announced the use of part of its idle raised funds for cash management, specifically investing in principal-protected financial products to enhance fund efficiency and shareholder returns [1][2][9]. Investment Overview - The investment amount for cash management is set at RMB 55 million [2]. - The funds are sourced from the net proceeds of a non-public offering approved by the China Securities Regulatory Commission, amounting to RMB 3,460,155,714.17, which was received on June 30, 2022 [2][3]. Investment Purpose - The purpose of this investment is to improve the efficiency and effectiveness of the raised funds while ensuring that it does not affect the construction of investment projects or the use of raised funds [2][9]. Investment Details - The company has approved the use of idle funds for principal-protected financial products with a maximum investment limit of RMB 1.5 billion, with individual product terms not exceeding 12 months [7][9]. - The financial products include structured deposits linked to the euro to US dollar exchange rate, with expected annualized returns ranging from 1.20% to 2.03% [6][8]. Risk Management - The financial products are categorized as principal-protected floating yield products, with overall risks being controllable. However, market fluctuations may still pose certain systemic risks [2][8]. - The company has established a risk control mechanism to monitor the investment and ensure the safety of funds [8]. Impact on the Company - The use of idle raised funds for cash management is designed to ensure that the progress of investment projects remains unaffected, thereby not significantly impacting the company's future business development, financial status, operating results, or cash flow [9]. - This strategy aims to enhance fund utilization efficiency and generate additional investment returns for shareholders [9].